| Full List of Protein(s) Regulating This Metabolite |
| Amino acid/auxin permease (AAAP) |
| Sodium-coupled neutral amino transporter 10 (SLC38A10) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[2] |
| Introduced Variation |
Overexpression of SLC38A10 |
| Induced Change |
Serine concentration: decrease |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that overexpression of SLC38A10 leads to the decrease of serine levels compared with control group. |
| Solute carrier family 38 member 2 (SLC38A2) |
Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[3] |
| Introduced Variation |
Knockdown (siRNA) of SLC38A2 |
| Induced Change |
Serine concentration: increase (FC = 1.75) |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that knockdown of SLC38A2 leads to the increase of serine levels compared with control group. |
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[4] |
| Introduced Variation |
Overexpression of SLC38A2 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that overexpression of SLC38A2 leads to the increase of serine levels compared with control group. |
| Solute carrier family 38 member 5 (SLC38A5) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[5] |
| Introduced Variation |
Overexpression of SLC38A5 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that overexpression of SLC38A5 leads to the increase of serine levels compared with control group. |
| Amino acid/polyamine transporter (AAPT) |
| Asc-type amino transporter 1 (SLC7A10) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[6] |
| Introduced Variation |
Overexpression of SLC7A10 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that overexpression of SLC7A10 leads to the increase of serine levels compared with control group. |
| Integral membrane E16 (SLC7A5) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[7] |
| Introduced Variation |
Overexperisson of SLC7A5 |
| Induced Change |
Serine concentration: decrease |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that co-overexperisson of SLC7A5 and SLC7A8 leads to the decrease of serine levels compared with control group. |
| L-type amino acid transporter 2 (LAT2) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[7] |
| Introduced Variation |
Overexperisson of SLC7A8 |
| Induced Change |
Serine concentration: decrease |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that co-overexperisson of SLC7A5 and SLC7A8 leads to the decrease of serine levels compared with control group. |
| Dicarboxylate/amino acid:cation symporter (DAACS) |
| Neutral amino acid transporter A (SLC1A4) |
Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[8] |
| Introduced Variation |
Overexpression of SLC1A4 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that overexpression of SLC1A4 leads to the increase of serine levels compared with control group. |
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[9] |
| Introduced Variation |
Knockout of SLC1A4 |
| Induced Change |
Serine concentration: decrease (FC = 0.10-0.20) |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that knockout of SLC1A4 leads to the decrease of serine levels compared with control group. |
| GPCR rhodopsin (GPCR-1) |
| Adrenergic receptor beta-3 (ADRB3) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[10] |
| Introduced Variation |
Agonist (CL-316,243) of Adrb3 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that agonist of ADRB3 leads to the increase of serine levels compared with control group. |
| GPCR secretin (GPCR-2) |
| Glucagon receptor (GCGR) |
Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[11] |
| Introduced Variation |
Antagonist (GRA1) of GCGR |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Hyperglycemic hyperosmolar syndrome [ICD-11: 5A20]
|
| Details |
It is reported that antagonist of GCGR leads to the increase of serine levels compared with control group. |
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[12] |
| Introduced Variation |
Knockout of Gcgr |
| Induced Change |
Serine concentration: increase (FC = 8.7) |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Type 2 diabetes mellitus [ICD-11: 5A11]
|
| Details |
It is reported that knockout of GCGR leads to the increase of serine levels compared with control group. |
| Hydrolases (EC 3) |
| Carnosine dipeptidase 1 (CNDP1) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[13] |
| Introduced Variation |
Knockout of Cndp1 |
| Induced Change |
Serine concentration: decrease (FC = 0.70) |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that knockout of Cndp1 leads to the decrease of serine levels compared with control group. |
| Glycerophosphodiester phosphodiesterase 1 (GDE1) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[14] |
| Introduced Variation |
Knockout of Gde1 |
| Induced Change |
Serine concentration: decrease (FC= 1.6) |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that knockout of Gde1 leads to the decrease of serine levels compared with control group. |
| Leukotriene-C4 hydrolase (GGT1) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[15] |
| Introduced Variation |
Knockdown (siRNA) of GGT1 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Renal cell carcinoma [ICD-11: 2C90]
|
| Details |
It is reported that knockdown of GGT1 leads to the increase of serine levels compared with control group. |
| Sulfatase sulf-1 (SULF1) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[16] |
| Introduced Variation |
Knockdown (shRNA) of SULF1 |
| Induced Change |
Serine concentration: decrease (FC = 0.47 / 0.48) |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Ovarian cancer [ICD-11: 2C73]
|
| Details |
It is reported that knockdown of SULF1 leads to the decrease of serine levels compared with control group. |
| Oxidoreductases (EC 1) |
| L-2-hydroxyglutarate dehydrogenase (L2HGDH) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[17] |
| Introduced Variation |
Mutation (Nonsense mutations or missense mutations) of L2hgdh |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Melanoma [ICD-11: 2C30]
|
| Details |
It is reported that mutation (nonsense mutations or missense mutations leading to KMT2D loss) of L2hgdh leads to the increase of serine levels compared with control group. |
| Phosphoglycerate dehydrogenase (PHGDH) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[18] |
| Introduced Variation |
Overexpression of PHGDH |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Breast cancer [ICD-11: 2C60]
|
| Details |
It is reported that overexpression of PHGDH leads to the increase of serine levels compared with control group. |
| Pore-forming PNC peptide (PNC) |
| Cellular tumor antigen p53 (TP53) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[19] |
| Introduced Variation |
Knockout of TP53 |
| Induced Change |
Serine concentration: increase (Log2 FC=1.27) |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Colon cancer [ICD-11: 2B90]
|
| Details |
It is reported that knockout of TP53 leads to the increase of serine levels compared with control group. |
| Transcription factor (TF) |
| Myc proto-oncogene protein (MYC) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[20] |
| Introduced Variation |
Knockdown (siRNA) of MYC |
| Induced Change |
Serine concentration: decrease |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Colorectal cancer [ICD-11: 2B91]
|
| Details |
It is reported that knockdown of MYC leads to the decrease of serine levels compared with control group. |
| Transcriptional coactivator (TC) |
| PPAR-gamma coactivator 1-alpha (PPARGC1A) |
Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[21] |
| Introduced Variation |
Knockout of Ppargc1a |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Congestive heart failure [ICD-11: BD10]
|
| Details |
It is reported that knockout of Ppargc1a leads to the increase of serine levels compared with control group. |
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[22] |
| Introduced Variation |
Overexpression of Ppargc1a |
| Induced Change |
Serine concentration: decrease |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that overexpression of Ppargc1a leads to the decrease of serine levels compared with control group. |
| Transferases (EC 2) |
| Acetylglucosaminyltransferase 5 (MGAT5) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[23] |
| Introduced Variation |
Knockout of Mgat5 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Healthy individual
|
| Details |
It is reported that knockout of Mgat5 leads to the increase of serine levels compared with control group. |
| Histone-lysine N-methyltransferase EHMT2 (EHMT2) |
Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[24] |
| Introduced Variation |
Inhibition (BIX01294 (BIX)) of EHMT2 |
| Induced Change |
Serine concentration: decrease |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Bone metastasis [ICD-11: 2E03]
|
| Details |
It is reported that inhibition of EHMT2 leads to the decrease of serine levels compared with control group. |
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[24] |
| Introduced Variation |
Overexpression of EHMT2 |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Bone metastasis [ICD-11: 2E03]
|
| Details |
It is reported that overexpression of EHMT2 leads to the increase of serine levels compared with control group. |
| Pyruvate kinase M2 (PKM) |
Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s)
|
| Detailed Information |
Protein Info
click to show the details of this protein
|
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[25] |
| Introduced Variation |
Knockdown (siRNA) of PKM |
| Induced Change |
Serine concentration: increase |
| Summary |
Introduced Variation
Induced Change
|
| Disease Status |
Lung cancer [ICD-11: 2C25]
|
| Details |
It is reported that knockdown of PKM leads to the increase of serine levels compared with control group. |
|
|
|
|
|
|
|